The nurse is preparing to administer a first dose of benztropine (Cogentin) to a patient diagnosed with parkinsonism. The nurse would notify the patient’s provider if the patient had a history of which condition?

A) Increased intraocular pressure: Sympathomimetic drugs stimulate the sympathetic nervous system and promote "fight or flight" responses, often resulting in vasoconstriction and other effects. Some sympathomimetics, especially those that affect alpha-adrenergic receptors, can lead to increased intraocular pressure, which is a concern in conditions like glaucoma.

B) Decreased blood pressure: Sympathomimetic drugs generally increase blood pressure by stimulating alpha and beta receptors that cause vasoconstriction and increased heart rate. In contrast, drugs that would decrease blood pressure are usually parasympathomimetics or other agents designed to block sympathetic responses.

C) Decreased heart rate: Sympathomimetic drugs typically increase heart rate by stimulating beta-1 adrenergic receptors in the heart. These drugs are used in situations requiring increased cardiac output or to counteract bradycardia. Decreased heart rate would typically occur with parasympathomimetic drugs or medications that block sympathetic activity (e.g., beta blockers).

D) Increased respiration: Sympathomimetic drugs can increase respiratory rate by promoting bronchodilation through beta-2 adrenergic receptor activation in the lungs. However, "increased respiration" as a general effect is not as specific or consistent as the other cardiovascular and ocular effects of these drugs. The primary and most prominent physiological change would be related to the cardiovascular effects.

A) “Alzheimer disease affects memory but not personality.”
While memory loss is one of the hallmark symptoms of Alzheimer’s disease, the condition also significantly impacts other cognitive functions, including personality and behavior. As the disease progresses, patients often experience changes in mood, behavior, and personality, such as increased irritability, depression, or aggression.

B) “With proper treatment, symptoms of this disease can be arrested.”
Currently, there is no cure for Alzheimer’s disease, and while some treatments (like cholinesterase inhibitors) can help manage symptoms temporarily or slow their progression, the disease itself is not arrestable. The goal of treatment is to manage symptoms and improve quality of life, but it cannot stop the disease from advancing.

C) “The onset of Alzheimer disease is usually between 65 and 75 years.”
While Alzheimer’s disease typically affects older adults, this statement is too narrow. Alzheimer’s disease can begin earlier, sometimes in individuals in their 50s or 60s, particularly in cases of early-onset Alzheimer’s. The average age of onset for most people is around 65, but there is variability.

D) “Alzheimer disease is a chronic, progressive condition.”
Alzheimer’s disease is indeed chronic (lasting for years) and progressive (it worsens over time). It gradually destroys brain cells, leading to a decline in cognitive function, including memory, thinking, and reasoning skills. This is the fundamental nature of the disease